Simulations Plus, Inc. (NASDAQ:SLP) Stock Has Consensus Price Target of $17.25

Shares of Simulations Plus, Inc. (NASDAQ:SLP) have been given an average rating of “Reduce” by the eight brokerages that are currently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating and seven have assigned a hold rating to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $17.25.

A number of analysts recently weighed in on SLP shares. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Simulations Plus in a research report on Tuesday, October 6th. BTIG Research reaffirmed a “neutral” rating on shares of Simulations Plus in a report on Wednesday, October 7th.

Simulations Plus Stock Performance

Simulations Plus stock opened at $18.50 on Tuesday. The stock has a 50 day moving average of $18.45 and a two-hundred day moving average of $17.19. Simulations Plus has a twelve month low of $11.09 and a twelve month high of $21.01. The stock has a market capitalization of $374.16 million, a price-to-earnings ratio of 46.25 and a beta of 1.31.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. Farther Finance Advisors LLC increased its stake in shares of Simulations Plus by 242.6% in the third quarter. Farther Finance Advisors LLC now owns 1,384 shares of the technology company’s stock worth $26,000 after acquiring an additional 980 shares during the last quarter. First Light Asset Management LLC increased its stake in shares of Simulations Plus by 6.1% in the second quarter. First Light Asset Management LLC now owns 2,792,677 shares of the technology company’s stock worth $51,134,000 after purchasing an additional 159,854 shares during the period. Integrated Wealth Concepts LLC acquired a new position in shares of Simulations Plus during the second quarter worth approximately $26,000. Groupe la Francaise bought a new stake in Simulations Plus in the 2nd quarter valued at $2,329,000. Finally, Susquehanna International Group LLP increased its stake in Simulations Plus by 76.2% during the second quarter. Susquehanna International Group LLP now owns 29,965 shares of the technology company’s stock valued at $549,000 after acquiring an additional 12,959 shares during the period. 78.08% of the stock is owned by institutional investors and hedge funds.

About Simulations Plus

Simulations Plus, Inc develops software and provides consulting services for pharmaceutical research and development. Its technology helps scientists model how drugs are absorbed, distributed, metabolized and excreted in the body, supporting decisions throughout the drug-development process.

The company’s product portfolio includes GastroPlus, a physiologically based pharmacokinetic modeling platform; ADMET Predictor, which supports the prediction of drug absorption, distribution, metabolism, excretion and toxicity properties; and DILIsym, a platform designed to evaluate the risk of drug-induced liver injury.